Claims
- 1. A method for providing an enhanced magnetic resonance image contrast of human or animal vascular tissue, nephric tissue or a combination thereof; said method comprising the steps of:
1.) administering to a human an effective amount, of a composition comprising:
a.) from about 0.01% to about 99.99% by weight, of a 1,4,8,11-tetraaza-bicyclo[6.6.2]hexadecane manganese (II) complex magnetic resonance imaging agent selected from the group: 29iv) and mixtures thereof; wherein each R is independently selected from the group consisting of:
i) C1-C18 hydrocarbyl; ii) —(CH2)nCO2—; iii) CH3(CH2)nCO—; iv) —(CH2)nR1; v) —(CH2)nOPO3−; vi) —[(CH2)nOPO3R2(phenyl)2]−; R1 is hydroxyl, 2-hydroxyphenyl, 2-pyridyl, 2-furfuryl, and mixtures thereof; R2 is C1-C12 linear, branched, or cyclic alkylene; R3 is selected from the group consisting of:
i) hydrogen; ii) C1-C18 hydrocarbyl; iii) —OH; iv) —(CH2)mCO2−; v) —O(CH2)mCO2—; vi) and mixtures thereof; the indices m and n have the value from 0 to about 10; X is a pharmaceutically compatible anion in sufficient amount q to provide electronic neutrality; and b.) the balance carriers and other adjunct ingredients; and
2.) imaging said human or animal's vascular tissue, nephric tissue or a combination thereof.
- 2. A method according to claim 1 wherein the serum blood levels of said agent is from about 0.001 moles to about 2 moles per liter.
- 3. A method for providing an enhanced magnetic resonance image contrast of human or animal vascular tissue, nephric tissue or a combination thereof; said method comprising the steps of:
1.) administering to a human or animal an effective amount of a composition comprising:
a.) from about 0.01% to about 99.99% by weight, of a 1,4,8,11-tetraazabicyclo[6.6.2]hexadecane manganese (II) complex magnetic resonance imaging agent selected from the group: 30iv) and mixtures thereof; wherein each R is independently selected from the group consisting of:
i) C1-C18 hydrocarbyl; ii) —(CH2)nCO2−; iii) CH3(CH2)nCO—; iv) —(CH2)nR1; v) —(CH2)nOPO3−; vi) —[(CH2)nOPO3R2(phenyl)2]−; R1 is hydroxyl, 2-hydroxyphenyl, 2-pyridyl, 2-furfuryl, and mixtures thereof; R2 is C1-C12 linear, branched, or cyclic alkylene; R3 is selected from the group consisting of:
i) hydrogen; ii) C1-C18 hydrocarbyl; iii) —OH; iv) —(CH2)mCO2—; v) —O(CH2)mCO2—; vi) and mixtures thereof; the indices m and n have the value from 0 to about 10; X is an pharmaceutically compatible anion in sufficient amount q to provide electronic neutrality; and b.) the balance carriers and other adjunct ingredients; and 2.) sustaining said effective amount of MRI agent for a period of time exceeding one hour; and 3.) imaging said human or animal's vascular tissue, nephric tissue or a combination thereof.
- 4. A method according to claim 3 wherein at least one R unit comprises —(CH2)nCO2—, and n is from 1 to 4.
- 5. A method according to claim 4 wherein n is 1.
- 6. A method according to claim 3 wherein each R unit comprises —(CH2)nCO2−, and n is from 1 to 4.
- 7. A method according to claim 1 wherein the tissue that is imaged comprises vascular tissue.
- 8. A method according to claim 1 wherein the tissue that is imaged comprises nephric tissue.
- 9. A method according to claim 2 wherein the tissue that is imaged comprises vascular tissue.
- 10. A method according to claim 2 wherein the tissue that is imaged comprises nephric tissue.
- 11. A method according to claim 3 wherein the tissue that is imaged comprises vascular tissue.
- 12. A method according to claim 3 wherein the tissue that is imaged comprises nephric tissue.
- 13. A method according to claim 4 wherein the tissue that is imaged comprises vascular tissue.
- 14. A method according to claim 4 wherein the tissue that is imaged comprises nephric tissue.
- 15. A method according to claim 5 wherein the tissue that is imaged comprises vascular tissue.
- 16. A method according to claim 5 wherein the tissue that is imaged comprises nephric tissue.
- 17. A method according to claim 6 wherein the tissue that is imaged comprises vascular tissue.
- 18. A method according to claim 6 wherein the tissue that is imaged comprises nephric tissue.
- 19. A method according to claim 1 wherein the tissue that is imaged consists essentially of vascular tissue.
- 20. A method according to claim 1 wherein the tissue that is imaged consists essentially nephric tissue.
- 21. A method according to claim 3 wherein the tissue that is imaged consists essentially of vascular tissue.
- 22. A method according to claim 4 wherein the tissue that is imaged consists essentially nephric tissue.
- 23. A solid pharmaceutical composition comprising:
a) from about 0.01% to about 99.99% by weight, of a 1,4,8,11-tetraazabicyclo[6.6.2]hexadecane manganese (II) complex magnetic resonance imaging agent selected from the group: 31iv) and mixtures thereof; wherein at least one R unit comprises —(CH2)CO2—, and the remaining R is independently selected from the group consisting of:
i) C1-C18 hydrocarbyl; ii) —(CH2)nCO2—; iii) CH3(CH2)nCO—; iv) —(CH2)nR1; v) —(CH2)nOPO3−; vi) —[(CH2)nOPO3R2(phenyl)2]−; R1 is hydroxyl, 2-hydroxyphenyl, 2-pyridyl, 2-furfuryl, and mixtures thereof; R2 is C1-C12 linear, branched, or cyclic alkylene; R3 is selected from the group consisting of:
i) hydrogen; ii) C1-C18 hydrocarbyl; iii) —OH; iv) —(CH2)mCO2—; v) —O(CH2)mCO213 ; vi) and mixtures thereof; the indices m and n have the value from 0 to about 10; X is an pharmaceutically compatible anion in sufficient amount q to provide electronic neutrality; and b) the balance comprising a pharmaceutically acceptable, solid inert filler.
Parent Case Info
[0001] This application is a continuation under 35 U.S.C. § 120 of U.S. application Ser. No. 09/957,392 filed on Sep. 20, 2001, which claims priority to U.S. Provisional Patent Application Serial No. 60/235,011 filed Sep. 25, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60235011 |
Sep 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09957392 |
Sep 2001 |
US |
Child |
10663586 |
Sep 2003 |
US |